Artemisinin-based combination therapy for ... - The Cochrane Library

5.2 DHA-P 3 doses 3 1116 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.09, 18.93]
6 Total Failure Day 28 PCR
adjusted
6 2171 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.19, 2.86]
6.1 DHA-P 4 doses 4 1067 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.10, 6.11]
6.2 DHA-P 3 doses 3 1104 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.08, 7.82]
Comparison 16. Artesunate Mefloquine dose analysis: FDC versus split dose regimen
Outcome or subgroup title
1 Total Failure Day 63 PCR
unadjusted
2 Total Failure Day 63 PCR
adjusted
No. of
studies
No. of
participants Statistical method Effect size
1 423 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.68, 1.27]
1 342 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.34, 1.28]
Comparison 17. Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-piperaquine)
Outcome or subgroup title
1 Total Failure Day 63 PCR
adjusted
2 Total Failure Day 28 PCR
adjusted
No. of
studies
No. of
participants Statistical method Effect size
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 279 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [0.23, 19.88]
Comparison 18. How does Dihydroartemisinin-piperaquine perform?
Outcome or subgroup title
1 Effectiveness: Total Failure (P.
falciparum) PCR adjusted
1.1 Day 63: DHA-P vs
Artesunate plus mefloquine
1.2 Day 42: DHA-P vs
Artemether-lumefantrine
1.3 Day 28: DHA-P vs
Artesunate plus amodiaquine
1.4 Day 42: DHA-P vs
Artesunate plus sulfadoxinepyrimethamine
No. of
studies
No. of
participants Statistical method Effect size
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4 1497 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.17, 1.83]
5 1337 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.29, 1.30]
2 629 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.13, 1.35]
1 161 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.39, 1.51]
121